Literature DB >> 23913152

Methods for conjugating antibodies to nanocarriers.

Anil Wagh1, Benedict Law.   

Abstract

Antibodies are one of the most commonly used targeting ligands for nanocarriers, mainly because they are specific, have a strong binding affinity, and are available for a number of disease biomarkers. The bioconjugation chemistry can be a crucial factor in determining the targeting efficiency of drug delivery and should be chosen on a case-by-case basis. An antibody consists of a number of functional groups which offer many flexible options for bioconjugation. This chapter focuses on discussing some of the approaches including periodate oxidation, carbodiimide, maleimide, and heterofunctional linkers, for conjugating antibodies to different nanocarriers. The advantages and limitations are described herein. Specific examples are selected to demonstrate the experimental procedures and to illustrate the potential for applying to other nanocarrier system.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23913152     DOI: 10.1007/978-1-62703-541-5_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival.

Authors:  Baharak Bahmani; Mayuko Uehara; Liwei Jiang; Farideh Ordikhani; Naima Banouni; Takaharu Ichimura; Zhabiz Solhjou; Georg J Furtmüller; Gerald Brandacher; David Alvarez; Ulrich H von Andrian; Kenji Uchimura; Qiaobing Xu; Ishaan Vohra; Osman A Yilmam; Yousef Haik; Jamil Azzi; Vivek Kasinath; Jonathan S Bromberg; Martina M McGrath; Reza Abdi
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

2.  A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer.

Authors:  Vanessa Bellat; Adam O Michel; Charlene Thomas; Tracy Stokol; Benjamin B Choi; Benedict Law
Journal:  Cancer Res       Date:  2022-04-01       Impact factor: 12.701

Review 3.  Targeting Tau to Treat Clinical Features of Huntington's Disease.

Authors:  Maria Masnata; Shireen Salem; Aurelie de Rus Jacquet; Mehwish Anwer; Francesca Cicchetti
Journal:  Front Neurol       Date:  2020-11-19       Impact factor: 4.003

4.  Targeting of sialoadhesin-expressing macrophages through antibody-conjugated (polyethylene glycol) poly(lactic-co-glycolic acid) nanoparticles.

Authors:  Sofie Van Hees; Kimberley Elbrink; Marjorie De Schryver; Peter Delputte; Filip Kiekens
Journal:  J Nanopart Res       Date:  2022-03-14       Impact factor: 2.533

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.